In the BioHarmony Drug Report Database
Tildrakizumab-asmn
Ilumya, Ilumetri (tildrakizumab) is an antibody pharmaceutical. Tildrakizumab was first approved as Ilumya on 2018-03-20. It is used to treat psoriasis in the USA. It has been approved in Europe to treat psoriasis. It is known to target interleukin-23 subunit alpha.
Trade Name
|
Ilumetri |
|---|---|
Common Name
|
tildrakizumab |
ChEMBL ID
|
CHEMBL2108681 |
Indication
|
psoriasis |
Drug Class
|
Monoclonal antibodies: humanized, interleukins as target |
Image (chem structure or protein)
